CTI 2024 | ACTO Chairman Dr. Akihiro Shimosaka: Exosomes Empower Innovative Breakthroughs in Immune Cell Therapy

CTI 2024 | ACTO Chairman Dr. Akihiro Shimosaka: Exosomes Empower Innovative Breakthroughs in Immune Cell Therapy

2024.12.05
From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. "Hematology Frontier" specially invited the conference chair and the chairman of the Asian Cellular Therapy Organization (ACTO), Dr. Akihiro Shimosaka, to share his profound insights on immune cell therapy, regenerative medicine, gene therapy, and the application of exosomes.
CTI 2024 | IACH Chairman Dr. Mohamad Mohty: Updates on the Latest Treatment Advances in GVHD

CTI 2024 | IACH Chairman Dr. Mohamad Mohty: Updates on the Latest Treatment Advances in GVHD

2024.12.05
From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During this conference, "Hematology Frontier" specially invited the conference chair and the chairman of the International Academy for Clinical Hematology (IACH), Dr. Mohamad Mohty from Sorbonne University , France, to share his insights on the latest treatment advances in Graft-Versus-Host Disease (GVHD), aiming to provide valuable insights for clinicians and researchers and to explore the future direction of GVHD treatment.
Dr. Yishan Ye on Donor Selection Trends: Insights from China’s Allogeneic Hematopoietic Stem Cell Transplantation Practice and the EBMT-China

Dr. Yishan Ye on Donor Selection Trends: Insights from China’s Allogeneic Hematopoietic Stem Cell Transplantation Practice and the EBMT-China

2024.12.04
From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China, attracting leading experts, scholars, and industry leaders in cellular and immune therapies. This international platform not only fosters academic exchange but also showcases the latest research breakthroughs and drives progress in the field. During the conference, Dr. Yishan Ye from The First Affiliated Hospital of Zhejiang University School of Medicine shared his insights in an interview with Hematology Frontier. He discussed the principles of donor selection in allogeneic hematopoietic stem cell transplantation (allo-HCT) and the findings from the EBMT-China collaboration. Here is the interview in full.
CTI 2024 | Professor Li Tang: Promising Horizons for CAR-T and mRNA Gene Therapy

CTI 2024 | Professor Li Tang: Promising Horizons for CAR-T and mRNA Gene Therapy

2024.12.04
From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China. This global event brought together leading experts, scholars, and industry pioneers in cellular and immune therapies, serving as both an academic platform and a showcase for the latest research breakthroughs. During the conference, Hematology Frontier launched the special column “Professor, Please Answer,” featuring on-the-spot interviews with prominent professors to capture their insights and visions for the future of the field. In this edition, we share the inspiring perspectives of Professor Li Tang from École Polytechnique Fédérale de Lausanne (EPFL), Switzerland.
CTI 2024丨Prof. Xi Zhang: New Developments and Challenges in Chronic Graft-Versus-Host Disease

CTI 2024丨Prof. Xi Zhang: New Developments and Challenges in Chronic Graft-Versus-Host Disease

2024.12.03
From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China, bringing together global leaders in cellular and immune therapies. This prestigious event served as a platform for academic exchange and a showcase for cutting-edge research in the field. During the conference, Prof. Xi Zhang from the Department of Hematology at Xinqiao Hospital , Army Medical University shared key insights on chronic graft-versus-host disease (cGVHD).
How I Treat丨Prof. Fengkui Zhang: My Approach to Treating Severe Aplastic Anemia

How I Treat丨Prof. Fengkui Zhang: My Approach to Treating Severe Aplastic Anemia

2024.12.03
Severe aplastic anemia (AA) remains a significant therapeutic challenge despite progress in its diagnosis and treatment. Issues such as difficulty in donor matching, side effects of immunosuppressive therapy (IST), and suboptimal hematologic responses demand continued exploration of innovative solutions. Prof. Fengkui Zhang of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences delivered a compelling presentation on treating severe aplastic anemia. In an interview with Hematology Frontier, Prof. Zhang shared insights into managing refractory aplastic anemia and the latest treatment advancements.
SIBCS 2024 | A Sneak Peek at Key Updates in the 2025 Edition of the “CBCS Little Red Book” from Top Experts

SIBCS 2024 | A Sneak Peek at Key Updates in the 2025 Edition of the “CBCS Little Red Book” from Top Experts

2024.12.03
The expert voting on key issues for the 2025 edition of the Guidelines and Standards for Breast Cancer Diagnosis and Treatment (Essential Version), also known as the CBCS Little Red Book, organized by the Chinese Anti-Cancer Association and the Chinese Medical Association’s Oncology Branch, has concluded. The new version is on the horizon! Oncology Frontier interviewed several prominent members of the advisory board who participated in the voting, including Prof. Yiding Chen, Prof. Hengyu Li, Prof. Man Li, Prof. Shu Liu, Prof. Yongsheng Wang, and Prof. Jian Zhang, to provide insights into the potential updates in the 2025 edition.